drugset / Trial / NCT01119456
A Study of IMC-RON8 in Advanced Solid Tumors
SequentialOpen-labelTreatment
Summary
A dose escalation study to determine the maximum tolerated dose of IMC-RON8 in participants with solid tumors. Participants can either be dosed once a week, or once every other week.
Timeline
- Start
- 2010-05
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NARNATUMAB | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | NARNATUMAB | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | NARNATUMAB | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | NARNATUMAB | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | NARNATUMAB | Monoclonal antibody | 25 mg/kg | Intravenous |
| Subject | NARNATUMAB | Monoclonal antibody | 30 mg/kg | Intravenous |
| Subject | NARNATUMAB | Monoclonal antibody | 35 mg/kg | Intravenous |
| Subject | NARNATUMAB | Monoclonal antibody | 40 mg/kg | Intravenous |